共 50 条
- [1] A PHASE I STUDY IN T CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD70 SIMPLE ANTIBODY™ ARGX-110HAEMATOLOGICA, 2016, 101 : 396 - 396Michot, J. M.Maerevoet, M.Aftimos, P.Rottey, S.Rolfo, C.Offner, F.Van Rompaey, L.Moshir, M.de Haard, H.Silence, K.Bagot, M.Pauwels, P.Zwaenepoel, K.Awada, A.Bron, D.Ribrag, V.
- [2] A PHASE I STUDY IN T CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD70 SIMPLE ANTIBODY T ARGX-110HAEMATOLOGICA, 2016, 101 : 105 - 105Michot, J. M.Silence, K.Maerevoet, M.Aftimos, P.Rottey, S.Rolfo, C.Offner, F.Van Rompaey, L.Moshir, M.de Haard, H.Bagot, M.Pauwels, P.Zwaenepoel, K.Awada, A.Bron, D.Ribrag, V.
- [3] Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesCLINICAL CANCER RESEARCH, 2017, 23 (21) : 6411 - 6420Aftimos, PhilippeRolfo, ChristianRottey, SylvieOffner, FritzBron, DominiqueMaerevoet, MarieSoria, Jean-CharlesMoshir, MahanDreier, TorstenVan Rompaey, LucMichot, Jean-MarieSilence, KarenHultberg, AnnaGandini, Domenicade Haard, HansRibrag, VincentPeeters, MarcThibault, AlainLeupin, NicolasAwada, Ahmad
- [4] Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical TrialBLOOD, 2018, 132Bagot, MartineMaerevoet, MarieZinzani, Pier LuigiOffner, FritzMorschhauser, FranckMichot, Jean-MarieRibrag, VincentBattistella, MaximeMoins, HeleneCalleri, AngelicaDalle, StephaneBeylot-Barry, MarieZwaenepoel, KarenDe Winnie, KoenMarie-Cardine, AnneCayuela, Jean-MichelTabanelli, ValentinaMotta, GiovannaMelle, FedericaHultberg, AnnaGandini, DomenicaMarafioti, TeresaMoshir, MahanDelahaye, TimZabrocki, PiotrSilence, KarenVan Rompaey, LucBensussan, ArmandDe Haard, HansPauwels, PatrickLeupin, NicolasPileri, Stefano A.
- [5] A phase I. first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Awada, AhmadRolfo, Christian D.Rottey, Sylviade Lendonck, Laure YsebrantSchroyens, Wilfrled A.Offner, FritzSilence, KarenDreier, TorstenMoshir, Mahande Heard, HansPosters, MarcBron, DominiqueThibault, AlainAftimos, Philippe G.
- [6] Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphomaBLOOD, 2015, 125 (12) : 1883 - 1889Duvic, MadeleinePinter-Brown, Lauren C.Foss, Francine M.Sokol, LubomirJorgensen, Jeffrey L.Challagundla, PramodaDwyer, Karen M.Zhang, XiaopingKurman, Michael R.Ballerini, RoccoLiu, LiKim, Youn H.
- [7] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's LymphomaBLOOD, 2010, 116 (21) : 1148 - 1149Christian, BethAlinari, LapoEarl, Christian TylerWilding, EmilyQuinion, CarlLustberg, MarkBenson, Don M., Jr.Jones, Jeffrey A.Byrd, John C.Wegener, William A.Goldenberg, David M.Baiocchi, Robert A.Blum, Kristie A.
- [8] Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasLEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3065 - 3070Martin, PeterFurman, Richard R.Rutherford, SarahRuan, JiaEly, ScottGreenberg, JuneColeman, MortonGoldsmith, Stanley J.Leonard, John P.
- [9] Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell LymphomaJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1591 - 1598Yamamoto, KazuhitoUtsunomiya, AtaeTobinai, KenseiTsukasaki, KunihiroUike, NaokuniUozumi, KimiharuYamaguchi, KazunariYamada, YasuakiHanada, ShuichiTamura, KazuoNakamura, ShigeoInagaki, HiroshiOhshima, KoichiKiyoi, HitoshiIshida, TakashiMatsushima, KoujiAkinaga, ShiroOgura, MichinoriTomonaga, MasaoUeda, Ryuzo
- [10] Phase I/II study of the anti-CD30 antibody MDX-060 in patients with refractory/relapsed CD30 positive lymphomaANNALS OF ONCOLOGY, 2005, 16 : 71 - 72Borchmann, PAnsell, SByrd, JHorwitz, SStrair, RKhan, KFischkoff, SYellin, MEngert, A